Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetes Therapy
Published in: Diabetes Therapy 1/2010

Open Access 01-08-2010 | Review

Diabetic gastroparesis: Therapeutic options

Authors: Uazman Alam, Omar Asghar, Rayaz Ahmed Malik

Published in: Diabetes Therapy | Issue 1/2010

Login to get access

Abstract

Gastroparesis is a condition characterized by delayed gastric emptying and the most common known underlying cause is diabetes mellitus. Symptoms include nausea, vomiting, abdominal fullness, and early satiety, which impact to varying degrees on the patient’s quality of life. Symptoms and deficits do not necessarily relate to each other, hence despite significant abnormalities in gastric emptying, some individuals have only minimal symptoms and, conversely, severe symptoms do not always relate to measures of gastric emptying. Prokinetic agents such as metoclopramide, domperidone, and erythromycin enhance gastric motility and have remained the mainstay of treatment for several decades, despite unwanted side effects and numerous drug interactions. Mechanical therapies such as endoscopic pyloric botulinum toxin injection, gastric electrical stimulation, and gastrostomy or jejunostomy are used in intractable diabetic gastroparesis (DG), refractory to prokinetic therapies. Mitemcinal and TZP-101 are novel investigational motilin receptor and ghrelin agonists, respectively, and show promise in the treatment of DG. The aim of this review is to provide an update on prokinetic and mechanical therapies in the treatment of DG.
Literature
1.
Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161:1989–1996.PubMedCrossRef
2.
Ricci JA, Siddique R, Stewart WF, Sandler RS, Sloan S, Farup CE. Upper gastrointestinal symptoms in a US national sample of adults with diabetes. Scand J Gastroenterol. 2000;35:152–159.PubMedCrossRef
3.
Samsom M, Bharucha A, Gerich JE, et al. Diabetes mellitus and gastric emptying: questions and issues in clinical practice. Diabetes Metab Res Rev. 2009;25:502–514.PubMedCrossRef
4.
5.
Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology. 1995;109:755–765.PubMedCrossRef
6.
Intagliata N, Koch KL. Gastroparesis in type 2 diabetes mellitus: prevalence, etiology, diagnosis, and treatment. Curr Gastroenterol Rep. 2007;9:270–279.PubMedCrossRef
7.
Barnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology. 1988;94:739–744.PubMed
8.
Lysy J, Israeli E, Strauss-Liviatan N, Goldin E. Relationships between hypoglycaemia and gastric emptying abnormalities in insulin-treated diabetic patients. Neurogastroenterol Motil. 2006;18:433–440.PubMedCrossRef
9.
Horowitz M, Jones KL, Rayner CK, Read NW. “Gastric” hypoglycaemia — an important concept in diabetes management. Neurogastroenterol Motil. 2006;18:405–407.PubMedCrossRef
10.
Ma J, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis: diagnosis and management. Drugs. 2009;69:971–986.PubMedCrossRef
11.
Hejazi R, McCallum R. Diabetic gastroparesis: a review of medical treatments. Pract Gastroenterol. 2009;6:10–20.
12.
Forster J, Damjanov I, Lin Z, Sarosiek I, Wetzel P, McCallum RW. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J Gastrointest Surg. 2005;9:102–108.PubMedCrossRef
13.
Lin Z, Sarosiek I, Forster J, Damjanov I, Hou Q, McCallum RW. Association of the status of interstitial cells of Cajal and electrogastrogram parameters, gastric emptying and symptoms in patients with gastroparesis. Neurogastroenterol Motil. 2009;22:56–61.PubMed
14.
Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug insight: from disturbed motility to disordered movement: a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3:138–148.PubMedCrossRef
15.
Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin.dependent) diabetes mellitus. Diabetologia. 1990;33:675–680.PubMedCrossRef
16.
Sogabe M, Okahisa T, Tsujigami K, et al. Ultrasonographic assessment of gastric motility in diabetic gastroparesis before and after attaining glycemic control. J Gastroenterol. 2005;40:583–590.PubMedCrossRef
17.
Schvarcz E, Palmér M, Aman J, Lindkvist B, Beckman KW. Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus. Diabetic Med. 1993;10:660–663.PubMedCrossRef
18.
Schvarcz E, Palmér M, Aman J, Berne C. Hypoglycemia increases the gastric emptying rate in healthy subjects. Diabetes Care. 1995;18:674–676.PubMedCrossRef
19.
Miller G, Palmer KR, Smith B, Ferrington C, Merrick MV. Smoking delays gastric emptying of solids. Gut. 1989;30:50–53.PubMedCrossRef
20.
Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24:1264–1269.PubMedCrossRef
21.
Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol. 2008;36:44–54.PubMedCrossRef
22.
Eliasson B, Björnsson E, Urbanavicius V, et al. Hyperinsulinaemia impairs gastrointestinal motility and slows carbohydrate absorption. Diabetologia. 1995;38:79–85.PubMedCrossRef
23.
Watkins CC, Sawa A, Jaffrey S, et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest. 2000;106:373–384.PubMedCrossRef
24.
Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32:762–768.PubMedCrossRef
25.
Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559–569.PubMed
26.
Cuthbertson J, Patterson S, O’Harte FP, Bell PM. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism. 2010. In Press.
27.
Little TJ, Pilichiewicz AN, Russo A, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab. 2006;91:1916–1923.PubMedCrossRef
28.
Vella A, Lee JS, Camilleri M, et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil. 2002;14:123–131.PubMedCrossRef
29.
Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol. 2000;278:946–951.
30.
Koch CA, Uwaifo GI. Are gastrointestinal symptoms related to diabetes mellitus and glycemic control? Eur J Gastroenterol Hepatol. 2008;20:822–825.PubMedCrossRef
31.
32.
Longstreth GF, Malagelada JR, Kelly KA. Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis. Ann Intern Med. 1977;86:195–196.PubMed
33.
Perkel MS, Moore C, Hersh T, Davidson ED. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig Dis Sci. 1979;24:662–666.PubMedCrossRef
34.
Peringer E, Jenner P, Marsden CD. Effect of metoclopramide on turnover of brain dopamine noradrenaline and 5-hydroxytryptamine. J Pharm Pharmacol. 1975;27:442–444.PubMedCrossRef
35.
Koch K. Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology, and tretment. Dig Dis Sci. 1999;44:1061–1075.PubMedCrossRef
36.
Schade RR, Dugas MC, Lhotsky DM, Gavaler JS, Van Thiel DH. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci. 1985;30:10–15.PubMedCrossRef
37.
Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care. 1993;16:1511–1514.PubMedCrossRef
38.
McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6:463–467.PubMedCrossRef
39.
Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985;7:25–32.PubMedCrossRef
40.
Snape WJ Jr., Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus. Ann Intern Med. 1982;96:444–446.PubMed
41.
42.
Tonini M., Cipolina L, Poluuzzi E, et al. Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19:379–390.PubMedCrossRef
43.
Parkman HP. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592–1622.PubMedCrossRef
44.
Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94:1230–1234.PubMed
45.
Farup CE, Leidy NK, Murray M, Williams GR, Helbers L, Quigley EM. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care. 1998;21:1699–1706.PubMedCrossRef
46.
Heer M, Muller-Duysing W, Benes I, et al. Diabetic gastroparesis: treatment with domperidone — a double-blind, placebo-controlled trial. Digestion. 1983;27:214–217.PubMedCrossRef
47.
Champion EA. Domperidone (Motilium) improves symptoms and solid phase gastric emptying in diabetic gastroparesis. Gastroenterol. 1987;82:975.
48.
Dumitrascu DL, Weinbeck M. Domperidone versus metoclopramide in the treatment of diabetic gastroparesis. Am J Gastroenterol. 2000;95:316–317.PubMedCrossRef
49.
Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2008;6:726–733.PubMedCrossRef
50.
51.
Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol. 1993;88:203–207.PubMed
52.
Janssens J, Peeters TL, Vantrappen G. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med. 1990;322:1028–1031.PubMedCrossRef
53.
Dive A, Miesse C, Galanti L, et al. Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. Crit Care Med. 1995;23:1356–1362.PubMedCrossRef
54.
Talley NJ, Verlinden M, Geenen DJ, et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut. 2001;49:395–401.PubMedCrossRef
55.
Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2000;14:1653–1661.PubMedCrossRef
56.
McCallum RW, Cynshi O. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis — a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther. 2007;26:1121–1130.PubMedCrossRef
57.
Hawkyard CV, Koerner RJ. The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. J Antimicrob Chemother. 2007;59:347–358.PubMedCrossRef
58.
McCallum RW, Prakash C, Campoli-Richards DM, Goa KL. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal disorders. Drugs. 1988;36:652–681.PubMedCrossRef
59.
Champion MC. Management of idiopathic, diabetic and miscellaneous gastroparesis with cisapride. Scand J Gastroenterol Suppl. 1989;165:44–52. Discussion:52–53.PubMedCrossRef
60.
Horowitz M, Maddern GJ, Maddox A, Wishart J, Chatterton BE, Shearman DJ. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology. 1987;93:311–315.PubMed
61.
Horowitz M, Maddox A, Harding PE, et al. Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology. 1987;92:1899–1907.PubMed
62.
63.
Havelund T, Oster-Jørgensen E, Eshøj O, Larsen ML, Lauritsen K. Effects of cisapride on gastroparesis in patients with insulin-dependent diabetes mellitus. Acta Medica Scandinavica. 1987;222:339–343.PubMedCrossRef
64.
Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab. 2000;85:4908–4911.PubMedCrossRef
65.
Peino R, Baldelli R, Rodriguez-Garcia J, et al. Ghrelin-induced growth hormone secretion in humans. Eur J Endocrinol. 2000;143:R11–R14.PubMedCrossRef
66.
Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000;141:4255–4261.PubMedCrossRef
67.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–660.PubMedCrossRef
68.
Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273:974–977.PubMedCrossRef
69.
Tack J, Depoortere I, Bisschops R, et al. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut. 2006;55:327–333.PubMedCrossRef
70.
Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992.PubMedCrossRef
71.
Druce MR. Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond). 2005;29:1130–1136.CrossRef
72.
Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer. 2008;98:300–308.PubMedCrossRef
73.
Murray CD, Martin NM, Patterson M, et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut. 2005;54:1693–1698.PubMedCrossRef
74.
Popescu I, Fleshner PR, Pezzullo JC, Charlton PA, Kosutic G, Senagore AJ. The Ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy: a randomized, dose-ranging, placebo-controlled clinical trial. Dis Colon Rectum. 2010;53:126–134.PubMedCrossRef
75.
Ejskjaer N, Dimcevski G, Wo J, et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil. 2010. In press.
76.
Ejskjaer N, Vestergaard ET, Hellström PM, et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther. 2009;29:1179–1187.PubMedCrossRef
77.
Lasseter KC, Shaughnessy L, Cummings D, et al. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2008;48:193–202.PubMedCrossRef
78.
Wang CP, Kao CH, Chen WK, Lo WY, Hsieh CL. A single-blinded, randomized pilot study evaluating effects of electroacupuncture in diabetic patients with symptoms suggestive of gastroparesis. J Altern Complement Med. 2008;14:833–839.PubMedCrossRef
79.
Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology. 1986;90:1919–1925.PubMed
80.
Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology. 1986;91:94–99.PubMed
81.
82.
Pehlivanov N, Pasricha PJ. Achalasia: botox, dilatation or laparoscopic surgery in 2006. Neurogastroenterol Motil. 2006;18:799–804.PubMedCrossRef
83.
84.
Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26:1251–1258.PubMedCrossRef
85.
Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103:416–423.PubMedCrossRef
86.
87.
Anand C, Al-Juburi A, Familoni B, et al. Gastric electrical stimulation is safe and effective: a long-term study in patients with drug-refractory gastroparesis in three regional centers. Digestion. 2007;75:83–89.PubMedCrossRef
88.
Abell TL, Malinowski S, Minocha A. Nutrition aspects of gastroparesis and therapies for drug-refractory patients. Nutr Clin Pract. 2006;21:23–33.PubMedCrossRef
89.
Cutts TF, Luo J, Starkebaum W, Rashed H, Abell TL. Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits? Neurogastroenterol Motil. 2005;17:35–43.PubMedCrossRef
90.
Maranki J, Parkman HP. Gastric electric stimulation for the treatment of gastroparesis. Curr Gastroenterol Rep. 2007;9:286–294.PubMedCrossRef
91.
Maranki JL, Lytes V, Meilahn JE, et al. Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis. Dig Dis Sci. 2008;53:2072–2078.PubMedCrossRef
92.
Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol. 2003;98:2122–2129.PubMedCrossRef
93.
Camilleri M, Malagelada JR. Abnormal intestinal motility in diabetics with the gastroparesis syndrome. Eur J Clin Invest. 1984;14:420–427.PubMedCrossRef
94.
Cashion AK, Holmes SL, Hathaway DK, Gaber AO. Gastroparesis following kidney pancreas transplant. Clin Transplant. 2004;18:306–311.PubMedCrossRef
95.
Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care. 2007;30:2608–2612.PubMedCrossRef
Metadata
Title
Diabetic gastroparesis: Therapeutic options
Authors
Uazman Alam
Omar Asghar
Rayaz Ahmed Malik
Publication date
01-08-2010
Publisher
Springer Healthcare Communications
Published in
Diabetes Therapy / Issue 1/2010
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-010-0010-8

Other articles of this Issue 1/2010

Diabetes Therapy 1/2010 Go to the issue

Review

The OmniPod Insulin Management System: the latest innovation in insulin pump therapy

Original Research

Intracellular magnesium of obese and type 2 diabetes mellitus children

Original Research

A longitudinal study into the new and long-term use of self-monitoring blood glucose strips in the UK

Letter from the Editor

Letter from the Editor
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits